glucocorticoid receptor signalling; and/or dyslipidemia, a metabolic disease, inflammation, or a neurodegenerative disease, in a subject.

[0009] In one ~~aspect~~example, provided are compounds having the structure of Formula I:



or a pharmaceutically acceptable salt thereof, wherein $\mathbf{R^{1a}}$ and $\mathbf{R^{1b}}$ are, independently, hydrogen, alkyl, alkoxy, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl, alkylene, or heteroalkylene, wherein when $\mathbf{R^{1a}}$ is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to $\mathbf{R^3}$ to form a 3-, 4-, 5-, 6-, 7-, or 8-membered heterocyclyl; $\mathbf{R^2}$ is hydrogen, alkylene, heteroalkylene, or an amino acid side chain, wherein when $\mathbf{R^2}$ is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to $\mathbf{R^3}$ to form a 4-, 5-, or 6-membered heterocyclyl; $\mathbf{R^3}$ is hydrogen, alkyl, alkylene, or heteroalkylene, wherein when $\mathbf{R^3}$ is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to $\mathbf{R^{1a}}$ or $\mathbf{R^2}$ to form the 3-, 4-, 5-, 6-, 7-, or 8 membered heterocyclyl; $\mathbf{R^4}$ is hydrogen or alkyl; $\mathbf{R^5}$ is oxygen, N$\mathbf{R^6}$, or sulfur; $\mathbf{R^6}$ is hydrogen or alkyl; **D*** is acyl, or a residue of a biologically active compound comprising hydroxyl, amino, or thiol; and **n** is zero, one, two, three, four, five, or six.

[0009a] In one aspect, provided is a compound having the following structure



or a pharmaceutically acceptable salt thereof, wherein $\mathbf{R^{1a}}$ and $\mathbf{R^{1b}}$ are, independently, hydrogen, alkyl, alkoxy, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl, alkylene, or heteroalkylene, wherein when $\mathbf{R^{1a}}$ is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to $\mathbf{R^3}$ to form a 3-, 4-, 5-, 6-, 7-, or 8-membered heterocyclyl; $\mathbf{R^2}$ is hydrogen, alkylene, heteroalkylene, or an amino acid side chain, wherein when $\mathbf{R^2}$ is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to $\mathbf{R^3}$ to form a 4-, 5-, or 6-membered heterocyclyl; $\mathbf{R^3}$ is hydrogen, alkyl, alkylene, or heteroalkylene, wherein when $\mathbf{R^3}$ is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to $\mathbf{R^{1a}}$ or $\mathbf{R^2}$ to form the 3-, 4-, 5-, 6-, 7-, or 8-membered heterocyclyl; $\mathbf{R^4}$ is hydrogen or alkyl; $\mathbf{R^5}$ is oxygen, N$\mathbf{R^6}$, or sulfur; $\mathbf{R^6}$ is hydrogen or

alkyl; **D*** is a residue of an anti-inflammatory biologically active compound comprising hydroxyl, amino, or thiol wherein the residue is a steroid or an LXR agonist; and **n** is zero, one, two, three, four, five, or six.

[0010] In one example, provided are compounds having the structure of Formula I:



(I)

or a pharmaceutically acceptable salt thereof, wherein $\mathbf{R^{1a}}$ and $\mathbf{R^{1b}}$ are, independently, hydrogen, alkyl, alkoxy, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl, alkylene, or heteroalkylene, wherein when $\mathbf{R^{1a}}$ is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to $\mathbf{R^3}$ to form a 4-, 5-, or 6-membered heterocyclyl; $\mathbf{R^2}$ is hydrogen, alkylene, heteroalkylene, or an amino acid side chain, wherein when $\mathbf{R^2}$ is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to $\mathbf{R^3}$ to form a 4-, 5-, or 6-membered heterocyclyl; $\mathbf{R^3}$ is hydrogen, alkyl, alkylene, or heteroalkylene, wherein when $\mathbf{R^3}$ is alkylene or heteroalkylene, the alkylene or heteroalkylene is

further bonded to $\mathbf{R^{1a}}$ or $\mathbf{R^2}$ to form the 4-, 5-, or 6-membered heterocyclyl; $\mathbf{R^4}$ is hydrogen or alkyl; $\mathbf{R^5}$ is oxygen, N$\mathbf{R^6}$, or sulfur; $\mathbf{R^6}$ is hydrogen or alkyl; **D*** is acyl, or a residue of a biologically active compound comprising hydroxyl, amino, or thiol; and **n** is zero, one, two, three, four, or five.

[0011] In another example, provided are linker-payload compounds having the structure of Formula II:



or a pharmaceutically acceptable salt thereof, wherein **L** is a linker comprising a moiety reactive with an antibody or an antigen binding fragment thereof; $\mathbf{R^{1a}}$ and $\mathbf{R^{1b}}$ are, independently, hydrogen, alkyl, alkoxy, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl, alkylene, or heteroalkylene, wherein when $\mathbf{R^{1a}}$ is alkylene or heteroalkylene, the alkylene or hetereoalkylene is further bonded to $\mathbf{R^3}$ to form a 3-, 4-, 5-, 6-, 7-, or 8-membered heterocyclyl; $\mathbf{R^2}$ is hydrogen, alkylene, heteroalkylene, or an amino acid side chain, wherein when $\mathbf{R^2}$ is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to $\mathbf{R^3}$ to form a 4-, 5-, or 6-membered heterocyclyl; $\mathbf{R^3}$ is hydrogen, alkyl, alkylene, or heteroalkylene, wherein when $\mathbf{R^3}$ is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to $\mathbf{R^{1a}}$ or $\mathbf{R^2}$ to form the 3-, 4-, 5-, 6-, 7-, or 8-membered heterocyclyl; $\mathbf{R^4}$ is hydrogen or alkyl; $\mathbf{R^5}$ is oxygen, N$\mathbf{R^6}$, or sulfur; $\mathbf{R^6}$ is hydrogen or alkyl; **D*** is acyl, or a residue of a biologically active compound comprising hydroxyl, amino, or thiol; and **n** is zero, one, two, three, four, five, or six.

[0011a] In another aspect, provided is a compound having the following structure



or a pharmaceutically acceptable salt thereof, wherein **L** is a linker comprising a moiety reactive with an antibody or an antigen binding fragment thereof; $\mathbf{R^{1a}}$ and $\mathbf{R^{1b}}$ are, independently, hydrogen, alkyl, alkoxy, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl, alkylene, or heteroalkylene, wherein when $\mathbf{R^{1a}}$ is alkylene or heteroalkylene, the alkylene or hetereoalkylene is further bonded to $\mathbf{R^3}$ to form a 3-, 4-, 5-, 6-, 7-, or 8-membered heterocyclyl; $\mathbf{R^2}$ is hydrogen, alkylene,

heteroalkylene, or an amino acid side chain, wherein when **R²** is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to **R³** to form a 4-, 5-, or 6-membered heterocyclyl; **R³** is hydrogen, alkyl, alkylene, or heteroalkylene, wherein when **R³** is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to **R^1a** or **R²** to form the 3-, 4-, 5-, 6-, 7-, or 8-membered heterocyclyl; **R⁴** is hydrogen or alkyl; **R⁵** is oxygen, N**R⁶**, or sulfur; **R⁶** is hydrogen or alkyl; **D*** is a residue of a biologically active compound comprising hydroxyl, amino, or thiol wherein the residue is a steroid or an LXR agonist; and **n** is zero, one, two, three, four, five, or six.

[0012] In another example, provided are linker-payloads having the structure of Formula II:



(II)

or a pharmaceutically acceptable salt thereof, wherein **L** is a linker comprising a moiety reactive with an antibody or an antigen binding fragment thereof; **R^1a** and **R^1b** are, independently, hydrogen, alkyl, alkoxy, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl, alkylene, or heteroalkylene, wherein when **R^1a** is alkylene or heteroalkylene, the alkylene or hetereoalkylene is further bonded to **R³** to

form a 4-, 5-, or 6-membered heterocyclyl; **R²** is hydrogen, alkylene, heteroalkylene, or an amino acid side chain, wherein when **R²** is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to **R³** to form a 4-, 5-, or 6-membered heterocyclyl; **R³** is hydrogen, alkyl, alkylene, or heteroalkylene, wherein when **R³** is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to **R^1a** or **R²** to form the 4-, 5-, or 6-membered heterocyclyl; **R⁴** is hydrogen or alkyl; **R⁵** is oxygen, N**R⁶**, or sulfur; **R⁶** is hydrogen or alkyl; **D*** is acyl, or a residue of a biologically active compound comprising hydroxyl, amino, or thiol; and **n** is zero, one, two, three, four, five, or six.

[0013] In another ~~aspect~~example, provided are compounds having the structure of Formula III:



wherein **L** is a linker; **BA** is a binding agent; **R^1a** and **R^1b** are, independently, hydrogen, alkyl, alkoxy, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl, alkylene, or heteroalkylene, wherein when **R^1a** is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to **R³** to form a 3-, 4-, 5-, 6-, 7-, or 8-membered heterocyclyl; **R²** is hydrogen, alkylene, heteroalkylene, or an amino acid side chain, wherein when **R²** is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to **R³** to form a 4-, 5-, or 6-membered heterocyclyl; **R³** is hydrogen, alkyl, alkylene, or heteroalkylene, wherein when **R³** is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to **R^1a** or **R²** to form the 3-, 4-, 5-, 6-, 7-, or 8-membered heterocyclyl; **R⁴** is hydrogen or alkyl; **R⁵** is oxygen, N**R⁶**, or sulfur; **R⁶** is hydrogen or alkyl; **D*** is a residue of a biologically active compound comprising hydroxyl, amino, or thiol; **n** is zero, one, two, three, four, five, or six; and **k** is an integer from one to thirty.

[0014] In another ~~aspect~~example, provided are compounds having the structure of Formula III:



wherein **L** is a linker; **BA** is a binding agent; $\mathbf{R^{1a}}$ and $\mathbf{R^{1b}}$ are, independently, hydrogen, alkyl, alkoxy, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl, alkylene, or heteroalkylene, wherein when $\mathbf{R^{1a}}$ is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to $\mathbf{R^3}$ to form a 3-, 4-, 5-, 6-, 7-, or 8-membered heterocyclyl; $\mathbf{R^2}$ is hydrogen, alkylene, heteroalkylene, or an amino acid side chain, wherein when $\mathbf{R^2}$ is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to $\mathbf{R^3}$ to form a 4-, 5-, or 6-membered heterocyclyl; $\mathbf{R^3}$ is hydrogen, alkyl, alkylene, or heteroalkylene, wherein when $\mathbf{R^3}$ is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to $\mathbf{R^{1a}}$ or $\mathbf{R^2}$ to form the 3-, 4-, 5-, 6-, 7-, or 8-membered heterocyclyl; $\mathbf{R^4}$ is hydrogen or alkyl; $\mathbf{R^5}$ is oxygen, N$\mathbf{R^6}$, or sulfur; $\mathbf{R^6}$ is hydrogen or alkyl; **D*** is a residue of an anti-inflammatory biologically active compound comprising hydroxyl, amino, or thiol; **n** is zero, one, two, three, four, five, or six; and **k** is an integer from one to thirty.

[0014a] In another aspect, the present disclosure refers to a compound having the following structure



wherein

L is a linker; **BA** is a binding agent; $\mathbf{R^{1a}}$ and $\mathbf{R^{1b}}$ are, independently, hydrogen, alkyl, alkoxy, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl, alkylene, or heteroalkylene, wherein when $\mathbf{R^{1a}}$ is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to $\mathbf{R^3}$ to form a 3-, 4-, 5-, 6-, 7-, or 8-membered heterocyclyl; $\mathbf{R^2}$ is hydrogen, alkylene, heteroalkylene, or an amino acid side chain, wherein when $\mathbf{R^2}$ is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to $\mathbf{R^3}$ to form a 4-, 5-, or 6-membered heterocyclyl; $\mathbf{R^3}$ is hydrogen, alkyl, alkylene, or heteroalkylene, wherein when $\mathbf{R^3}$ is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to $\mathbf{R^{1a}}$ or $\mathbf{R^2}$ to form the 3-, 4-, 5-, 6-, 7-, or 8-membered heterocyclyl; $\mathbf{R^4}$ is hydrogen or alkyl; $\mathbf{R^5}$ is oxygen, N$\mathbf{R^6}$, or sulfur; $\mathbf{R^6}$ is hydrogen or alkyl; **D*** is a residue of an anti-inflammatory biologically active compound comprising hydroxyl, amino, or thiol wherein the residue is a steroid or an LXR agonist; **n** is zero, one, two, three, four, five, or six; and **k** is an integer from one to thirty.

[0014b] In another aspect, the present disclosure refers to a compound having the following structure



wherein

L is a linker; **BA** is a binding agent; $\mathbf{R^{1a}}$ and $\mathbf{R^{1b}}$ are, independently, hydrogen, alkyl, alkoxy, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl, alkylene, or heteroalkylene, wherein when $\mathbf{R^{1a}}$ is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to $\mathbf{R^3}$ to form a 3-, 4-, 5-, 6-, 7-, or 8-membered heterocyclyl; $\mathbf{R^2}$ is hydrogen, alkylene, heteroalkylene, or an amino acid side chain, wherein when $\mathbf{R^2}$ is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to $\mathbf{R^3}$ to form a 4-, 5-, or 6-membered heterocyclyl; $\mathbf{R^3}$ is hydrogen, alkyl, alkylene, or heteroalkylene, wherein when $\mathbf{R^3}$ is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to $\mathbf{R^{1a}}$ or $\mathbf{R^2}$ to form the 3-, 4-, 5-, 6-, 7-, or 8-membered heterocyclyl; $\mathbf{R^4}$ is hydrogen or alkyl; $\mathbf{R^5}$ is oxygen, N$\mathbf{R^6}$, or sulfur; $\mathbf{R^6}$ is hydrogen or alkyl; **D*** is a residue of an anti-inflammatory biologically active compound comprising hydroxyl, or aminowherein the residue is a steroid or an LXR agonist; **n** is zero, one, two, three, four, five, or six; and **k** is an integer from one to thirty.

[~~0014a~~0014c] In another aspect, the present disclosure refers to a compound having the following structure



wherein



L is a linker comprising ; **BA** is a binding agent; $\mathbf{R^{1a}}$ and $\mathbf{R^{1b}}$ are, independently, hydrogen, alkyl, alkoxy, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl, alkylene, or heteroalkylene, wherein when $\mathbf{R^{1a}}$ is alkylene or heteroalkylene, the alkylene or heteroalkylene is

further bonded to **R**^{3} to form a 3-, 4-, 5-, 6-, 7-, or 8-membered heterocyclyl; **R**^{2} is hydrogen, alkylene, heteroalkylene, or an amino acid side chain, wherein when **R**^{2} is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to **R**^{3} to form a 4-, 5-, or 6-membered heterocyclyl; **R**^{3} is hydrogen, alkyl, alkylene, or heteroalkylene, wherein when **R**^{3} is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to **R**^{1a} or **R**^{2} to form the 3-, 4-, 5-, 6-, 7-, or 8-membered heterocyclyl; **R**^{4} is hydrogen or alkyl; **R**^{5} is oxygen, N**R**^{6}, or sulfur; **R**^{6} is hydrogen or alkyl; **D*** is an anti-inflammatory residue of a biologically active compound comprising hydroxyl, amino, or thiol wherein the residue is a steroid or an LXR agonist; **n** is zero, one, two, three, four, five, or six; and **k** is an integer from one to thirty.

[0015] In another example, provided are compounds having the structure of Formula III:



wherein **L** is a linker comprising PAB or PABC; **BA** is a binding agent; **R**^{1a} and **R**^{1b} are, independently, hydrogen, alkyl, alkoxy, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl, alkylene, or heteroalkylene, wherein when **R**^{1a} is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to **R**^{3} to form a 3-, 4-, 5-, 6-, 7-, or 8-membered heterocyclyl; **R**^{2} is hydrogen, alkylene, heteroalkylene, or an amino acid side chain, wherein when **R**^{2} is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to **R**^{3} to form a 4-, 5-, or 6-membered heterocyclyl; **R**^{3} is hydrogen, alkyl, alkylene, or heteroalkylene, wherein when **R**^{3} is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to **R**^{1a} or **R**^{2} to form the 3-, 4-, 5-, 6-, 7-, or 8-membered heterocyclyl; **R**^{4} is hydrogen or alkyl; **R**^{5} is oxygen, N**R**^{6}, or sulfur; **R**^{6} is hydrogen or alkyl; **D*** is a residue of a biologically active compound comprising hydroxyl, amino, or thiol; **n** is zero, one, two, three, four, five, or six; and **k** is an integer from one to thirty.

[0016] In another ~~aspect~~example, provided are compunds having the structure of Formula III:



wherein **L** is a linker; **BA** is a binding agent; $\mathbf{R^{1a}}$ and $\mathbf{R^{1b}}$ are, independently, hydrogen, alkyl, alkoxy, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl, alkylene, or heteroalkylene, wherein when $\mathbf{R^{1a}}$ is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to $\mathbf{R^3}$ to form a 3-, 4-, 5-, 6-, 7-, or 8-membered heterocyclyl; $\mathbf{R^2}$ is hydrogen, alkylene, heteroalkylene, or an amino acid side chain, wherein when $\mathbf{R^2}$ is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to $\mathbf{R^3}$ to form a 4-, 5-, or 6-membered heterocyclyl; $\mathbf{R^3}$ is hydrogen, alkyl, alkylene, or heteroalkylene, wherein when $\mathbf{R^3}$ is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to $\mathbf{R^{1a}}$ or $\mathbf{R^2}$ to form the 3-, 4-, 5-, 6-, 7-, or 8-membered heterocyclyl; $\mathbf{R^4}$ is hydrogen or alkyl; $\mathbf{R^5}$ is oxygen, $\mathbf{NR^6}$, or sulfur; $\mathbf{R^6}$ is hydrogen or alkyl; **D*** is a residue of a biologically active compound comprising hydroxyl, amino, or thiol; **n** is zero, one, two, three, four, five, or six; wherein conjugation of **L** to **BA** is selected from the group consisting of a click chemistry residue, an amide residue, and a residue comprising two cysteine residues of a single **BA** that are chemically bonded to **L**; and **k** is an integer from one to thirty.

[0016a] In another aspect, provided is a compound having the following structure



wherein

L is a linker; **BA** is a binding agent; $\mathbf{R^{1a}}$ and $\mathbf{R^{1b}}$ are, independently, hydrogen, alkyl, alkoxy, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl, alkylene, or heteroalkylene, wherein when $\mathbf{R^{1a}}$ is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to $\mathbf{R^3}$ to form a 3-, 4-, 5-, 6-, 7-, or 8-membered heterocyclyl; $\mathbf{R^2}$ is hydrogen, alkylene, heteroalkylene, or an amino acid side chain, wherein when $\mathbf{R^2}$ is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to $\mathbf{R^3}$ to form a 4-, 5-, or 6-membered heterocyclyl; $\mathbf{R^3}$ is hydrogen, alkyl, alkylene, or heteroalkylene, wherein when $\mathbf{R^3}$ is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to $\mathbf{R^{1a}}$ or $\mathbf{R^2}$ to form the 3-, 4-, 5-, 6-, 7-, or 8-membered heterocyclyl; $\mathbf{R^4}$ is

hydrogen or alkyl; **R**^{5} is oxygen, N**R**^{6}, or sulfur; **R**^{6} is hydrogen or alkyl; **D*** is a residue of an anti-inflammatory biologically active compound comprising hydroxyl, amino, or thiol wherein the residue is a steroid or an LXR agonist; **n** is zero, one, two, three, four, five, or six; wherein conjugation of **L** to **BA** is selected from the group consisting of a click chemistry residue, an amide residue, and a residue comprising two cysteine residues of a single **BA** that are chemically bonded to **L**; and **k** is an integer from one to thirty.

[0017] In another example, provided are compounds having the structure of Formula III:



(III)

wherein **L** is a linker; **BA** is a binding agent; **R**^{1a} and **R**^{1b} are, independently, hydrogen, alkyl, alkoxy, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl, alkylene, or heteroalkylene, wherein when **R**^{1a} is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to **R**^{3} to form a 4-, 5-, or 6-membered heterocyclyl; **R**^{2} is hydrogen, alkylene, heteroalkylene, or an amino acid side chain, wherein when **R**^{2} is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to **R**^{3} to form a 4-, 5-, or 6-membered heterocyclyl; **R**^{3} is hydrogen, alkyl, alkylene, or heteroalkylene,

[0023a] In another aspect, the present disclosure refers to an antibody-drug conjugate comprising an antibody, or an antigen binding fragment thereof, where said antibody or antigen binding fragment thereof is conjugated to a compound as disclosed herein.

[0023b] In another aspect, the present disclosure refers to a pharmaceutical composition comprising the compound as disclosed herein, and a pharmaceutically acceptable excipient, carrier, or diluent.

[0023c] In another aspect, the present disclosure refers to compound as disclosed herein or the pharmaceutical composition as disclosed herein for use in therapy.

[0023d] In another aspect, the present disclosure refers to a use of compound as disclosed herein or the pharmaceutical composition as disclosed herein in the manufacture of a medicament for treating a disease, disorder, or condition associated with glucocorticoid receptor signaling in a subject comprising that the compound is to be administered to the subject wherein the disease, disorder, or condition is metabolic, inflammatory, or neurodegenerative.

[0023e] In another aspect, the present disclosure refers to a use of the compound as disclosed herein or the pharmaceutical composition as disclosed herein in the manufacture of a medicament for treating dyslipidemia, a metabolic disease, inflammation, or a neurodegenerative disease in a subject.

[0023f] In another aspect, the present disclosure refers to a use of the compound as disclosed herein or the pharmaceutical composition as disclosed herein in the manufacture of a medicament for treating dyslipidemia in a subject.

[0023g] In another aspect, the present disclosure refers to a use of the compound as disclosed herein or the pharmaceutical composition as disclosed herein in the manufacture of a medicament for treating a metabolic disease in a subject.

[0023h] In another aspect, the present disclosure refers to a use of the compound as disclosed herein or the pharmaceutical composition as disclosed herein in the manufacture of a medicament for treating in a subject.

[0023i] In another aspect, the present disclosure refers to a use of the compound as disclosed herein or the pharmaceutical composition as disclosed herein in the manufacture of a medicament for treating a neurodegenerative disease in a subject.

[0023j] In another aspect, the present disclosure refers to a method of preparing an antibody-drug conjugate comprising contacting a binding agent with a compound as disclosed herein.

[0023k] In another aspect, the present disclosure refers to a compound selected from the group consisting of

WHAT IS CLAIMED IS:

1. A compound having the following structure



wherein

L is a linker;

BA is a binding agent;

R^{1a} and **R^{1b}** are, independently, hydrogen, alkyl, alkoxy, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl, alkylene, or heteroalkylene, wherein when **R^{1a}** is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to **R^3** to form a 3-, 4-, 5-, 6-, 7-, or 8-membered heterocyclyl;

R^2 is hydrogen, alkylene, heteroalkylene, or an amino acid side chain, wherein when **R^2** is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to **R^3** to form a 4-, 5-, or 6-membered heterocyclyl;

R^3 is hydrogen, alkyl, alkylene, or heteroalkylene, wherein when **R^3** is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to **R^{1a}** or **R^2** to form the 3-, 4-, 5-, 6-, 7-, or 8-membered heterocyclyl;

R^4 is hydrogen or alkyl;

R^5 is oxygen, N**R^6**, or sulfur;

R^6 is hydrogen or alkyl;

D* is a residue of an anti-inflammatory biologically active compound comprising hydroxyl, amino, or thiol wherein the residue is a steroid or an LXR agonist;

n is zero, one, two, three, four, five, or six; and

k is an integer from one to thirty.

~~2. The compound of claim 1, wherein **D*** is a residue of an anti-inflammatory biologically active compound comprising hydroxyl, amino, or thiol.~~

~~3~~2. The compound of claim ~~2~~1, wherein the anti-inflammatory biologically active compound is a steroid or a residue thereof.

~~4~~3. The compound of claim ~~2~~1, wherein the anti-inflammatory biologically active compound is an LXR agonist or a residue thereof.

~~5~~4. A compound having the following structure



wherein

L is a linker;

BA is a binding agent;

R^{1a} and **R^{1b}** are, independently, hydrogen, alkyl, alkoxy, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl, alkylene, or heteroalkylene, wherein when **R^{1a}** is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to **R^{3}** to form a 3-, 4-, 5-, 6-, 7-, or 8-membered heterocyclyl;

R^{2} is hydrogen, alkylene, heteroalkylene, or an amino acid side chain, wherein when **R^{2}** is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to **R^{3}** to form a 4-, 5-, or 6-membered heterocyclyl;

R^{3} is hydrogen, alkyl, alkylene, or heteroalkylene, wherein when **R^{3}** is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to **R^{1a}** or **R^{2}** to form the 3-, 4-, 5-, 6-, 7-, or 8-membered heterocyclyl;

R^{4} is hydrogen or alkyl;

R^{5} is oxygen, N**R^{6}**, or sulfur;

R^{6} is hydrogen or alkyl;

D* is a residue of an anti-inflammatory biologically active compound comprising hydroxyl, or amino~~, or thiol~~ wherein the residue is a steroid or an LXR agonist;

n is zero, one, two, three, four, five, or six; and

k is an integer from one to thirty.

~~65~~. The compound of claim ~~54~~, wherein **D*** is a residue of a steroid comprising hydroxyl or~~,~~ amino~~, or thiol~~.

~~76~~. A compound having the following structure



wherein



L is a linker comprising ;

BA is a binding agent;

R^{1a} and **R^{1b}** are, independently, hydrogen, alkyl, alkoxy, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl, alkylene, or heteroalkylene, wherein when **R^{1a}** is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to **R^{3}** to form a 3-, 4-, 5-, 6-, 7-, or 8-membered heterocyclyl;

R^{2} is hydrogen, alkylene, heteroalkylene, or an amino acid side chain, wherein when **R^{2}** is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to **R^{3}** to form a 4-, 5-, or 6-membered heterocyclyl;

R^{3} is hydrogen, alkyl, alkylene, or heteroalkylene, wherein when **R^{3}** is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to **R^{1a}** or **R^{2}** to form the 3-, 4-, 5-, 6-, 7-, or 8-membered heterocyclyl;

R^{4} is hydrogen or alkyl;

R^{5} is oxygen, N**R^{6}**, or sulfur;

R^{6} is hydrogen or alkyl;

D* is a residue of an anti-inflammatory biologically active compound comprising hydroxyl, amino, or thiol wherein the residue is a steroid or an LXR agonist;

n is zero, one, two, three, four, five, or six; and

k is an integer from one to thirty.



~~87~~87. The compound of claim ~~76~~76, wherein **L** is a linker comprising , and $\mathbf{R^2}$ is hydrogen.

~~98~~98. A compound having the following structure



wherein

L is a linker;

BA is a binding agent;

$\mathbf{R^{1a}}$ and $\mathbf{R^{1b}}$ are, independently, hydrogen, alkyl, alkoxy, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl, alkylene, or heteroalkylene, wherein when $\mathbf{R^{1a}}$ is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to $\mathbf{R^3}$ to form a 3-, 4-, 5-, 6-, 7-, or 8-membered heterocyclyl;

$\mathbf{R^2}$ is hydrogen, alkylene, heteroalkylene, or an amino acid side chain, wherein when $\mathbf{R^2}$ is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to $\mathbf{R^3}$ to form a 4-, 5-, or 6-membered heterocyclyl;

$\mathbf{R^3}$ is hydrogen, alkyl, alkylene, or heteroalkylene, wherein when $\mathbf{R^3}$ is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to $\mathbf{R^{1a}}$ or $\mathbf{R^2}$ to form the 3-, 4-, 5-, 6-, 7-, or 8-membered heterocyclyl;

$\mathbf{R^4}$ is hydrogen or alkyl;

$\mathbf{R^5}$ is oxygen, N$\mathbf{R^6}$, or sulfur;

$\mathbf{R^6}$ is hydrogen or alkyl;

D* is a residue of an anti-inflammatory biologically active compound comprising hydroxyl, amino, or thiol wherein the residue is a steroid or an LXR agonist;

n is zero, one, two, three, four, five, or six;

wherein conjugation of **L** to **BA** is selected from the group consisting of a click chemistry residue, an amide residue, and a residue comprising two cysteine residues of a single **BA** that are chemically bonded to **L**; and

k is an integer from one to thirty.

~~10~~9. The compound of claim 1, having the following structure



wherein

L is a linker;

BA is a binding agent;

R^{1a} and **R^{1b}** are, independently, hydrogen, alkyl, alkoxy, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl, alkylene, or heteroalkylene, wherein when **R^{1a}** is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to **R^3** to form a 4-, 5-, or 6-membered heterocyclyl;

R^2 is hydrogen, alkylene, heteroalkylene, or an amino acid side chain, wherein when **R^2** is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to **R^3** to form a 4-, 5-, or 6-membered heterocyclyl;

R^3 is hydrogen, alkyl, alkylene, or heteroalkylene, wherein when **R^3** is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to **R^{1a}** or **R^2** to form the 4-, 5-, or 6-membered heterocyclyl;

R^4 is hydrogen or alkyl;

R^5 is oxygen, N**R^6**, or sulfur;

R^6 is hydrogen or alkyl;

D* is a residue of an anti-inflammatory biologically active compound comprising hydroxyl, amino, or thiol wherein the residue is a steroid or an LXR agonist;

n is zero, one, two, three, four, five, or six; and

k is an integer from one to thirty.

~~11~~10. The compound of claim ~~10~~ 9 having the structure



wherein

L is a linker;

BA is a binding agent;

R^{1a} and **R^{1b}** are, independently, hydrogen, alkyl, alkoxy, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl, or alkylene, wherein when **R^{1a}** is alkylene, the alkylene is further bonded to **R^{3}** to form a 4-, 5-, or 6-membered heterocyclyl;

R^{2} is hydrogen or an amino acid side chain;

R^{3} is hydrogen, alkyl, or alkylene, wherein when **R^{3}** is alkylene, the alkylene is further bonded to **R^{1a}** to form the 4-, 5-, or 6-membered heterocyclyl;

D* is a residue of an anti-inflammatory biologically active compound comprising hydroxyl wherein the residue is a steroid or an LXR agonist;

n is zero, one, two, three, four, five, or six; and

k is an integer from one to thirty.

~~12~~11. The compound of claim ~~10~~ 9 having the following structure



wherein

L is a linker;

BA is a binding agent;

R^{1a} and **R^{1b}** are, independently, hydrogen, alkyl, alkoxy, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl, or alkylene, wherein when **R^{1a}** is alkylene, the alkylene is further bonded to **R^{3}** to form a 4-, 5-, or 6-membered heterocyclyl;

R^{2} is hydrogen or an amino acid side chain;

R^3 is hydrogen, alkyl, or alkylene, wherein when **R^3** is alkylene, the alkylene is further bonded to **R^{1a}** to form the 4-, 5-, or 6-membered heterocyclyl;

D* is a residue of an anti-inflammatory biologically active compound comprising hydroxyl wherein the residue is a steroid or an LXR agonist;

n is zero, one, two, three, four, five, or six; and

k is an integer from one to thirty.

~~13~~12. The compound of any one of claims 1-~~12~~11, wherein the linker comprises



.

~~14~~13. The compound of claim ~~10~~9, wherein the compound is



wherein

SP^1 and **SP^2**, when present, are spacer groups wherein **SP^1** further comprises a moiety reactive with an antibody or an antigen binding fragment thereof;

each **AA** is an amino acid; and

p is an integer from 1 to 10.

~~15~~14. The compound of claim ~~14~~13, wherein **SP^1** comprises a reactive group that comprises an alkyne.

~~16~~15. The compound of claim ~~15~~14, wherein the alkyne is capable of participating in a 1,3-cycloaddition reaction.

~~17~~16. The compound of claim ~~16~~15, wherein the alkyne is capable of participating in a 1,3-cycloaddition reaction with the binding agent, wherein the binding agent is an azido-functionalized binding agent.

~~18~~17. The compound of claim ~~14~~13, wherein **SP²** comprises  .

~~19~~18. The compound of claim ~~14~~13, wherein **SP²** comprises  , and **R²** is hydrogen or alkyl.

~~20~~19. The compound of claim ~~17~~16, wherein the alkyne is capable of participating in a 1,3-cycloaddition reaction with the binding agent, the binding agent is an azido-functionalized binding agent, and **SP²** comprises  .

~~21~~20. The compound of claim ~~17~~16, wherein the alkyne is capable of participating in a 1,3-cycloaddition reaction with the binding agent, the binding agent is an azido-functionalized binding agent, **SP²** comprises  , and **R²** is hydrogen or alkyl.

~~22~~21. The compound of claim ~~14~~13, wherein the binding agent is an antibody modified with a primary amine compound according to the Formula H_2N-**LL**-**X**, wherein **LL** is a divalent linker selected from the group consisting of

a divalent polyethylene glycol (PEG) group;

–$(CH_2)_{\mathbf{n}}$–;

–$(CH_2CH_2O)_{\mathbf{n}}$-$(CH_2)_p$–;

–$(CH_2)_{\mathbf{n}}$-N(H)C(O)-$(CH_2)_{\mathbf{m}}$–;

–$(CH_2CH_2O)_{\mathbf{n}}$-N(H)C(O)-$(CH_2CH_2O)_{\mathbf{m}}$-$(CH_2)_{\mathbf{p}}$–;

–$(CH_2)_{\mathbf{n}}$-C(O)N(H)-$(CH_2)_{\mathbf{m}}$–;

–$(CH_2CH_2O)_{\mathbf{n}}$-C(O)N(H)-$(CH_2CH_2O)_{\mathbf{m}}$-$(CH_2)_{\mathbf{p}}$–;

–$(CH_2)_{\mathbf{n}}$-N(H)C(O)-$(CH_2CH_2O)_{\mathbf{m}}$-$(CH_2)_{\mathbf{p}}$–;

–$(CH_2CH_2O)_{\mathbf{n}}$-N(H)C(O)-$(CH_2)_{\mathbf{m}}$–;

–$(CH_2)_{\mathbf{n}}$-C(O)N(H)-$(CH_2CH_2O)_{\mathbf{m}}$-$(CH_2)_{\mathbf{p}}$–; and

–$(CH_2CH_2O)_{\mathbf{n}}$-C(O)N(H)-$(CH_2)_{\mathbf{m}}$–,

wherein

n is an integer selected from 1 to 12;

m is an integer selected from 0 to 12;

p is an integer selected from 0 to 2; and

X is selected from the group consisting of –SH, $–N_3$, –C≡CH, –C(O)H, tetrazole,  ,

 ,  ,  , and  .

~~23~~22. The compound of claim ~~22~~21, wherein the binding agent is an antibody modified with a primary amine having the following structure

 .

~~24~~23. The compound of claim ~~23~~22, wherein the compound is selected from the group consisting of



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;


BA
k

;


BA
k

;



;



;



;



;



;



;






BA
H
N
O
O
O
N
N
N
O
O
H
N
O
O
H
N
O
O
H
N
O
O
H
N
O
O
HO
H
H
HO
F
O
k

;


BA
N
H
O
O
O
N
N
N
O
O
H
N
O
O
H
N
O
O
H
N
O
O
HO
H
H
HO
F
O
k

;



;



;





;


BA
NH
k

;


BA
k

;























;



;



;



;



;



;






BA
H
N
O
N
N
N
O
O
O
O
O
O
O
O
O
O
O
O
O
HN
O
O
O
O
O
O
O
O
O
O
O
O
O



;



;



;



;



;









;



;



;



;



;



;

wherein **k** is 1, 2, 3, or 4.

~~25~~24. The compound of claim 1, wherein the compound is selected from the group consisting of



,



,



,



,



, and





,



,



, and



; wherein **z** is 1, 2, 3, or 4.

~~26~~25. The compound of claim ~~10~~9, wherein **BA** is an antibody or antigen-binding fragment thereof.

~~27~~26. The compound of claim ~~26~~25, wherein **BA** is a transglutaminase-modified antibody or antigen-binding fragment thereof comprising at least one glutamine residue used for conjugation.

~~28~~27. The compound of claim ~~26~~25, wherein **BA** is a transglutaminase-modified antibody or antigen-binding fragment thereof comprising at least two glutamine residues used for conjugation.

~~29~~28. The compound of claim ~~26~~25, wherein **BA** is a transglutaminase-modified antibody or antigen-binding fragment thereof comprising at least four glutamine residues used for conjugation.

~~30~~29. The compound of claim ~~29~~28, wherein **BA** is a transglutaminase-modified antibody or antigen-binding fragment thereof, wherein conjugation is at two Q295 residues; and **k** is 2.

~~31~~30. The compound of claim ~~29~~28, wherein **BA** is a transglutaminase-modified antibody or antigen-binding fragment thereof, wherein conjugation is at two Q295 residues and two N297Q residues; and **k** is 4.

~~32~~31. A compound having the following structure



or a pharmaceutically acceptable salt thereof, wherein

R^{1a} and **R^{1b}** are, independently, hydrogen, alkyl, alkoxy, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl, alkylene, or heteroalkylene, wherein when **R^{1a}** is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to **R^{3}** to form a 3-, 4-, 5-, 6-, 7-, or 8-membered heterocyclyl;

R^{2} is hydrogen, alkylene, heteroalkylene, or an amino acid side chain, wherein when **R^{2}** is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to **R^{3}** to form a 4-, 5-, or 6-membered heterocyclyl;

R³ is hydrogen, alkyl, alkylene, or heteroalkylene, wherein when **R³** is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to **R¹ᵃ** or **R²** to form the 3-, 4-, 5-, 6-, 7-, or 8-membered heterocyclyl;

R⁴ is hydrogen or alkyl;

R⁵ is oxygen, N**R⁶**, or sulfur;

R⁶ is hydrogen or alkyl;

D* is ~~acyl, or~~ a residue of an anti-inflammatory biologically active compound comprising hydroxyl, amino, or thiol wherein the residue is a steroid or an LXR agonist; and

n is zero, one, two, three, four, five, or six.

~~33~~32. The compound of claim ~~32~~31, having the following structure



or a pharmaceutically acceptable salt thereof, wherein

R¹ᵃ and **R¹ᵇ** are, independently, hydrogen, alkyl, alkoxy, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl, alkylene, or heteroalkylene, wherein when **R¹ᵃ** is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to **R³** to form a 4-, 5-, or 6-membered heterocyclyl;

R² is hydrogen, alkylene, heteroalkylene, or an amino acid side chain, wherein when **R²** is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to **R³** to form a 4-, 5-, or 6-membered heterocyclyl;

R³ is hydrogen, alkyl, alkylene, or heteroalkylene, wherein when **R³** is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to **R¹ᵃ** or **R²** to form the 4-, 5-, or 6-membered heterocyclyl;

R⁴ is hydrogen or alkyl;

R⁵ is oxygen, N**R⁶**, or sulfur;

R⁶ is hydrogen or alkyl;

D* is ~~acyl, or~~ a residue of a biologically active compound comprising hydroxyl, amino, or thiol wherein the residue is a steroid or an LXR agonist; and

n is zero, one, two, three, four, or five.

~~34~~33. The compound of claim ~~33~~ 32 having the following structure



or a pharmaceutically acceptable salt thereof, wherein

R^{1a} and **R^{1b}** are, independently, hydrogen, alkyl, alkoxy, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl, or alkylene, wherein when **R^{1a}** is alkylene, the alkylene is further bonded to **R^{3}** to form a 4-, 5-, or 6-membered heterocyclyl;

R^{2} is hydrogen or an amino acid side chain;

R^{3} is hydrogen, alkyl, or alkylene, wherein when **R^{3}** is alkylene, the alkylene is further bonded to **R^{1a}** to form the 4-, 5-, or 6-membered heterocyclyl;

D* is ~~acyl, or~~ a residue of an anti-inflammatory biologically active compound comprising hydroxyl wherein the residue is a steroid or an LXR agonist; and

n is zero, one, two, three, four, or five.

~~35~~34. The compound of claim ~~33~~32, wherein the compound has the following structure



.

~~36~~35. The compound of one of claims ~~32~~31-~~35~~34, wherein **R^{1a}** and **R^{1b}** are each hydrogen.

~~37~~36. The compound of any one of claims ~~32~~31-~~36~~35, wherein **n** is two.

~~38~~37. The compound of any one of claims ~~32~~31-~~37~~36, wherein **n** is two and **R^{2}** is hydrogen or methyl.

~~39~~38. The compound of any one of claims ~~32~~31-~~38~~37, wherein **n** is two, **R^{2}** is hydrogen or methyl, **R^{3}** is hydrogen, and **D*** is a residue of a biologically active compound comprising hydroxyl wherein the residue is a steroid or an LXR agonist.

~~40~~39. The compound of claim ~~39~~38, wherein the compound is selected from the group consisting of:



,



, and



; or

a pharmaceutically acceptable salt thereof.

~~41~~40. The compound of claim ~~36~~35, wherein **n** is one.

~~42~~41. The compound of claim ~~41~~40, wherein $\mathbf{R^2}$ is hydrogen, methyl, or $–CH_2Ph$.

~~43~~42. The compound of claim ~~42~~41, wherein $\mathbf{R^3}$ is hydrogen.

~~44~~43. The compound of claim ~~43~~42, wherein **D*** is a residue of a biologically active compound comprising hydroxyl wherein the residue is a steroid or an LXR agonist.

~~45~~44. The compound of claim ~~44~~43, wherein the compound is selected from the group consisting of:


,


,


,


,


,


, and


; or

a pharmaceutically acceptable salt thereof.

~~46~~45. The compound of claim ~~41~~40, wherein **R^2** is hydrogen or methyl.

~~47~~46. The compound of claim ~~46~~45, wherein **R^3** is alkyl.

~~48~~47. The compound of claim ~~47~~46, wherein **D*** is a residue of a biologically active compound comprising hydroxyl wherein the residue is a steroid or an LXR agonist.

~~49~~48. The compound of claim ~~48~~47, wherein the compound is selected from the group consisting of



and


, or a pharmaceutically acceptable salt thereof.

~~50~~49. The compound of claim ~~33~~32, wherein **R^{1a}** is alkyl or arylalkyl, and **R^{1b}** is hydrogen.

~~51~~50. The compound of claim ~~50~~49, wherein **n** is one.

~~52~~51. The compound of claim ~~51~~50, wherein **R^2** is hydrogen.

~~53~~52. The compound of claim ~~52~~51, wherein **R^3** is hydrogen.

~~54~~53. The compound of claim ~~53~~52, wherein **D*** is a residue of a biologically active compound comprising hydroxyl wherein the residue is a steroid or an LXR agonist.

~~55~~54. The compound of claim ~~54~~53, wherein the compound is selected from the group consisting of

 and  ; or a pharmaceutically acceptable salt thereof.

~~56~~55. The compound of claim ~~33~~32, wherein $\mathbf{R^{1a}}$ is alkylene, where the alkylene is further bonded to $\mathbf{R^3}$ to form a 4-, 5-, or 6-membered heterocyclyl;
$\mathbf{R^{1b}}$ is hydrogen; and
$\mathbf{R^3}$ is alkylene further bonded to $\mathbf{R^{1a}}$ to form the 4-, 5-, or 6-membered heterocyclyl.

~~57~~56. The compound of claim ~~56~~55, wherein **n** is one.

~~58~~57. The compound of claim ~~57~~56, wherein $\mathbf{R^2}$ is hydrogen.

~~59~~58. The compound of claim ~~58~~57, wherein **D*** is a residue of a biologically active compound comprising hydroxyl wherein the residue is a steroid or an LXR agonist.

~~60~~59. The compound of claim ~~59~~58, wherein the compound is selected from the group consisting of


,

, and

; or a pharmaceutically acceptable salt thereof.

~~61~~60. The compound of claim ~~41~~40, wherein the compound is


.

~~62~~61. The compound of claim ~~36~~35, wherein the compound is selected from the group

consisting of  and  .

~~63~~62. The compound of claim ~~41~~40, wherein $\mathbf{R^2}$ is alkylene, wherein the alkylene is further bonded to $\mathbf{R^3}$ to form a 6-membered heterocyclyl; and

$\mathbf{R^3}$ is alkylene, wherein the alkylene is further bonded to $\mathbf{R^2}$ to form the 6-membered heterocyclyl.

~~64~~63. The compound of claim ~~63~~62, wherein **D*** is a residue of a biologically active compound comprising hydroxyl wherein the residue is a steroid or an LXR agonist.

~~65~~64. The compound of claim ~~64~~63, wherein the compound is



; or a pharmaceutically acceptable salt thereof.

~~66~~65. A compound having the following structure



or a pharmaceutically acceptable salt thereof, wherein

L is a linker comprising a moiety reactive with an antibody or an antigen binding fragment thereof;

$\mathbf{R^{1a}}$ and $\mathbf{R^{1b}}$ are, independently, hydrogen, alkyl, alkoxy, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl, alkylene, or heteroalkylene, wherein when $\mathbf{R^{1a}}$ is alkylene or heteroalkylene, the alkylene or hetereoalkylene is further bonded to $\mathbf{R^3}$ to form a 3-, 4-, 5-, 6-, 7-, or 8-membered heterocyclyl;

$\mathbf{R^2}$ is hydrogen, alkylene, heteroalkylene, or an amino acid side chain, wherein when $\mathbf{R^2}$ is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to $\mathbf{R^3}$ to form a 4-, 5-, or 6-membered heterocyclyl;

$\mathbf{R^3}$ is hydrogen, alkyl, alkylene, or heteroalkylene, wherein when $\mathbf{R^3}$ is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to $\mathbf{R^{1a}}$ or $\mathbf{R^2}$ to form the 3-, 4-, 5-, 6-, 7-, or 8-membered heterocyclyl;

$\mathbf{R^4}$ is hydrogen or alkyl;

$\mathbf{R^5}$ is oxygen, N$\mathbf{R^6}$, or sulfur;

$\mathbf{R^6}$ is hydrogen or alkyl;

D* is ~~acyl, or~~ a residue of a biologically active compound comprising hydroxyl, amino, or thiol wherein the residue is a steroid or an LXR agonist; and

n is zero, one, two, three, four, five, or six.

~~67. The compound of claim 66, wherein when **D*** is a residue of a biologically active compound comprising hydroxyl, amino, or thiol, then the biologically active compound or residue thereof is an anti-inflammatory biologically active compound or residue thereof.~~

~~68~~66. The compound of claim ~~67~~65, wherein the anti-inflammatory biologically active compound is a steroid or a residue thereof.

~~69~~67. The compound of claim ~~67~~65, wherein the anti-inflammatory biologically active compound is an LXR agonist or a residue thereof.

~~70~~68. The compound of claim ~~66~~65, having the following structure



or a pharmaceutically acceptable salt thereof, wherein

L is a linker comprising a moiety reactive with an antibody or an antigen binding fragment thereof;

R^{1a} and **R^{1b}** are, independently, hydrogen, alkyl, alkoxy, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl, alkylene, or heteroalkylene, wherein when **R^{1a}** is alkylene or heteroalkylene, the alkylene or hetereoalkylene is further bonded to **R^3** to form a 4-, 5-, or 6-membered heterocyclyl;

R^2 is hydrogen, alkylene, heteroalkylene, or an amino acid side chain, wherein when **R^2** is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to **R^3** to form a 4-, 5-, or 6-membered heterocyclyl;

R^3 is hydrogen, alkyl, alkylene, or heteroalkylene, wherein when **R^3** is alkylene or heteroalkylene, the alkylene or heteroalkylene is further bonded to **R^{1a}** or **R^2** to form the 4-, 5-, or 6-membered heterocyclyl;

R^4 is hydrogen or alkyl;

R^{5} is oxygen, N**R**^{6}, or sulfur;

R^{6} is hydrogen or alkyl;

D* is ~~acyl, or~~ a residue of an anti-inflammatory biologically active compound comprising hydroxyl, amino, or thiol wherein the residue is a steroid or an LXR agonist; and

n is zero, one, two, three, four, five, or six.

~~71~~69. The compound of claim ~~70~~ 68 having the following structure



or a pharmaceutically acceptable salt thereof, wherein

L is a linker comprising a moiety reactive with an antibody or an antigen binding fragment thereof;

R^{1a} and **R**^{1b} are, independently, hydrogen, alkyl, alkoxy, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl, or alkylene, wherein when **R**^{1a} is alkylene, the alkylene is further bonded to **R**^{3} to form a 4-, 5-, or 6-membered heterocyclyl;

R^{2} is hydrogen or an amino acid side chain;

R^{3} is hydrogen, alkyl, or alkylene, wherein when **R**^{3} is alkylene, the alkylene is further bonded to **R**^{1a} to form the 4-, 5-, or 6-membered heterocyclyl;

D* is ~~acyl, or~~ a residue of an anti-inflammatory biologically active compound comprising hydroxyl wherein the residue is a steroid or an LXR agonist; and

n is zero, one, two, three, four, five, or six.

~~72~~70. The compound of claim ~~70~~ 68 having the following structure



or a pharmaceutically acceptable salt thereof, wherein

L is a linker comprising a moiety reactive with an antibody or an antigen binding fragment thereof;

R^{1a} and **R^{1b}** are, independently, hydrogen, alkyl, alkoxy, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl, or alkylene, wherein when **R^{1a}** is alkylene, the alkylene is further bonded to **R^{3}** to form a 4-, 5-, or 6-membered heterocyclyl;

R^{2} is hydrogen or an amino acid side chain;

R^{3} is hydrogen, alkyl, or alkylene, wherein when **R^{3}** is alkylene, the alkylene is further bonded to **R^{1a}** to form the 4-, 5-, or 6-membered heterocyclyl;

D* is ~~acyl, or~~ a residue of an anti-inflammatory biologically active compound comprising hydroxyl wherein the residue is a steroid or an LXR agonist; and

n is zero, one, two, three, four, five, or six.

~~73~~71. The compound of any one of claims ~~66~~65-~~72~~70, wherein the linker further comprises



.

~~74~~72. The compound of claim ~~70~~68, wherein the compound is



or a pharmaceutically acceptable salt thereof, wherein

SP^{1} and **SP^{2}**, when present, are spacer groups wherein **SP^{1}** further comprises a moiety reactive with an antibody or an antigen binding fragment thereof;

each **AA** is an amino acid; and

p is an integer from 1 to 10.

~~75~~73. The compound of claim ~~74~~72, wherein **SP^{1}** comprises a reactive group that comprises an alkyne.

~~76~~74. The compound of claim ~~75~~73, wherein the alkyne is capable of participating in a 1,3-cycloaddition reaction.

~~77~~75. The compound of claim ~~66~~65, wherein the alkyne is capable of participating in a 1,3-cycloaddition reaction with an azide to form regioisomeric 1,2,3-triazolyl moieties, wherein the azide comprises an azido-functionalized binding agent.

~~78~~76. The compound of claim ~~74~~72, wherein **SP²** comprises  .

~~79~~77. The compound of claim ~~74~~72, wherein **SP²** comprises  , and **R²** is hydrogen or alkyl.

~~80~~78. The compound of claim ~~77~~75, wherein the alkyne is capable of participating in a 1,3-cycloaddition reaction with an azide to form regioisomeric 1,2,3-triazolyl moieties, the azide comprises an azido-functionalized binding agent, and **SP²** comprises  .

~~81~~79. The compound of claim ~~77~~75, wherein the alkyne is capable of participating in a 1,3-cycloaddition reaction with an azide to form regioisomeric 1,2,3-triazolyl moieties, the azide comprises an azido-functionalized binding agent, **SP²** comprises  , and **R²** is hydrogen or alkyl.

~~82~~80. The compound of claim ~~74~~72, wherein

R^{1a} and **R^{1b}** are hydrogen;

R^{2} is hydrogen or methyl;

R^{3} is hydrogen; and

n is two.

~~83~~81. The compound of claim ~~82~~80, wherein **D*** is a residue of a biologically active compound comprising hydroxyl wherein the residue is a steroid or an LXR agonist.

~~84~~82. The compound of claim ~~83~~81, selected from the group consisting of



;



; and



; or

a pharmaceutically acceptable salt thereof.

~~85~~83. The compound of claim ~~74~~72, wherein

R^{1a} and **R^{1b}** are hydrogen;

R^{2} is hydrogen, methyl, or –CH_2Ph;

R^{3} is hydrogen or alkyl; and

n is one.

~~86~~84. The compound of claim ~~85~~83, wherein **D*** is a residue of a biologically active compound comprising hydroxyl wherein the residue is a steroid or an LXR agonist.

~~87~~85. The compound of claim ~~86~~84, selected from the group consisting of



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



; and



; or a pharmaceutically acceptable salt thereof.

~~88~~86. The compound of claim ~~74~~72, wherein

R^{1a} and **R^{1b}** are hydrogen;

R^{2} is hydrogen;

R^{3} is alkyl; and

n is one.

~~89~~87. The compound of claim ~~88~~86, wherein **D*** is a residue of a biologically active compound comprising hydroxyl wherein the residue is a steroid or an LXR agonist.

~~90~~88. The compound of claim ~~89~~ 87 having a structure



; or a pharmaceutically acceptable salt thereof.

~~91~~89. The compound of claim ~~74~~72, wherein

R^{1a} is alkyl or arylalkyl;

R^{1b} is hydrogen;

R^{2} is hydrogen;

R^{3} is hydrogen; and

n is one.

~~92~~90. The compound of claim ~~91~~89, wherein **D*** is a residue of a biologically active compound comprising hydroxyl wherein the residue is a steroid or an LXR agonist.

~~93~~91. The compound of claim ~~92~~90, selected from the group consisting of



; and



; or

a pharmaceutically acceptable salt thereof.

~~94~~92. The compound of claim ~~74~~72, wherein

R^{1a} is alkylene, further bonded to **R^{3}** to form a 4-, 5-, or 6-membered heterocyclyl;

R^{1b} is hydrogen;

R^{2} is hydrogen;

R^{3} is alkylene further bonded to **R^{1a}** to form the 4-, 5-, or 6-membered heterocyclyl; and

n is one.

~~95~~93. The compound of claim ~~94~~92, wherein **D*** is a residue of a biologically active compound comprising hydroxyl wherein the residue is a steroid or an LXR agonist.

~~96~~94. The compound of claim ~~95~~93, selected from the group consisting of



; and



; or

a pharmaceutically acceptable salt thereof.

~~97~~95. The compound of claim ~~95~~93, having the structure



or a pharmaceutically acceptable salt thereof.

~~98~~96. The compound of claim ~~70~~68, wherein

R^{1a} and **R^{1b}** are hydrogen;

R^{2} is hydrogen;

R^{3} is hydrogen; and

n is one.

~~99~~97. The compound of claim ~~98~~96, wherein **D*** is a residue of a biologically active compound comprising hydroxyl wherein the residue is a steroid or an LXR agonist.

~~100~~98. The compound of claim ~~99~~97, having the following structure



or

a pharmaceutically acceptable salt thereof.

~~101~~99. The compound of claim ~~70~~68, wherein

R^{1a} and **R^{1b}** are hydrogen;

R^{2} is hydrogen or –CH_2Ph;

R^{3} is hydrogen; and

n is four.

~~102~~100. The compound of claim ~~101~~99, wherein **D*** is a residue of a biologically active compound comprising hydroxyl wherein the residue is a steroid or an LXR agonist.

~~103~~101. The compound of claim ~~102~~100, selected from the group consisting of



;



; and



; or a pharmaceutically acceptable salt thereof.

~~104~~102. The compound of claim ~~72~~70, wherein

R^{1a} and **R^{1b}** are hydrogen;

R^{3} is hydrogen; and

n is zero.

~~105~~103. The compound of claim ~~104~~102, wherein **D*** is a residue of a biologically active compound comprising hydroxyl wherein the residue is a steroid or an LXR agonist.

~~106~~104. The compound of claim ~~105~~103, selected from the group consisting of



and



; or a pharmaceutically acceptable salt thereof.

~~107~~105. The compound of claim ~~88~~86, wherein

$\mathbf{R^{1a}}$ and $\mathbf{R^{1b}}$ are hydrogen;

$\mathbf{R^{2}}$ is hydrogen;

$\mathbf{R^{3}}$ is alkyl;

$\mathbf{R^{4}}$ is alkyl; and

n is one.

~~108~~106. The compound of claim ~~107~~105, wherein **D*** is a residue of a biologically active compound comprising hydroxyl wherein the residue is a steroid or an LXR agonist.

~~109~~107. The compound of claim ~~108~~106, having the following structure



; or a pharmaceutically acceptable salt thereof.

~~110~~108. The compound of claim ~~70~~68, wherein

R^{1a} and **R^{1b}** are hydrogen;

R^{2} is hydrogen or –CH_2OH;

R^{3} is hydrogen; and

n is six.

~~111~~109. The compound of claim ~~110~~108, wherein **D*** is a residue of a biologically active compound comprising hydroxyl wherein the residue is a steroid or an LXR agonist.

~~112~~110. The compound of claim ~~111~~109, having the following structure



or a pharmaceutically acceptable salt thereof.

~~113~~111. The compound of claim ~~74~~72, wherein

R^{1a} and **R^{1b}** are hydrogen;

R^{2} is alkylene, wherein the alkylene is further bonded to **R^{3}** to form a 6-membered heterocyclyl;

R^{3} is alkylene, wherein the alkylene is further bonded to **R^{2}** to form the 6-membered heterocyclyl; and

n is one.

~~114~~112. The compound of claim ~~113~~111, wherein **D*** is a residue of a biologically active compound comprising hydroxyl wherein the residue is a steroid or an LXR agonist.

~~115~~113. The compound of claim ~~114~~112, wherein the compound is



; or a pharmaceutically acceptable salt thereof.

~~116~~114. The compound of claim ~~84~~82, wherein the compound is



or a pharmaceutically acceptable salt thereof.

~~117~~115. The compound of claim ~~84~~82, wherein the compound is



or a pharmaceutically acceptable salt thereof.

~~118~~116. The compound of claim ~~96~~94, wherein the compound is



or a pharmaceutically acceptable salt thereof.

~~119~~117. The compound of claim ~~87~~85, wherein the compound is



or a pharmaceutically acceptable salt thereof.

~~120~~118. The compound of claim ~~87~~85, wherein the compound is



or a pharmaceutically acceptable salt thereof.

~~121~~119. An antibody-drug conjugate comprising an antibody, or an antigen binding fragment thereof, where said antibody or antigen binding fragment thereof is conjugated to a compound of claim ~~32~~ 31 or ~~66~~65.

~~122~~120. The antibody-drug conjugate of claim ~~121~~119, wherein the BA-L is bonded to a moiety selected from the group consisting of


;


;


;


;


;


;


;


;


;


;


;


;


;


;


;


;


;


;



;



; and



.

~~123~~121. An antibody-drug conjugate comprising an antibody, or an antigen binding fragment thereof, where said antibody or antigen binding fragment thereof is conjugated to a compound of claim ~~33~~ 32 or ~~70~~68.

~~124~~122. A pharmaceutical composition comprising the compound of any one of claims 1-~~120~~121, and a pharmaceutically acceptable excipient, carrier, or diluent.

~~125~~123. The compound of any one of claims 1-~~120~~ 121 or the pharmaceutical composition of claim ~~124~~ 122 for use in therapy.

~~126~~124. Use of the compound of any one of claims 1-~~120~~ 121 or the pharmaceutical composition of claim ~~124~~ 122 in the manufacture of a medicament for treating a disease, disorder, or condition associated with glucocorticoid receptor signaling in a subject comprising that the compound is to be administered to the subject wherein the disease, disorder, or condition is metabolic, inflammatory, or neurodegenerative.

~~127~~125. The use of claim ~~126~~124, wherein the disease, disorder, or condition, is an inflammatory disease, disorder, or condition.

~~128~~126. The use of claim ~~126~~ 124 or ~~127~~125, wherein side effects associated with administration of the unconjugated steroid payload of said compound are reduced.

~~129~~127. Use of the compound of any one of claims 1-~~120~~ 121 or the pharmaceutical composition of claim ~~124~~ 122 in the manufacture of a medicament for treating dyslipidemia, a metabolic disease, inflammation, or a neurodegenerative disease in a subject.

~~130~~128. Use of the compound of any one of claims 1-~~120~~ 121 or the pharmaceutical composition of claim ~~124~~ 122 in the manufacture of a medicament for treating dyslipidemia in a subject.

~~131~~129. Use of the compound of any one of claims 1-~~120~~ 121 or the pharmaceutical composition of claim ~~124~~ 122 in the manufacture of a medicament for treating a metabolic disease.

~~132~~130. Use of the compound of any one of claims 1-~~120~~ 121 or the pharmaceutical composition of claim ~~124~~ 122 in the manufacture of a medicament for treating inflammation in a subject.

~~133~~131. Use of the compound of any one of claims 1-~~120~~ 121 or the pharmaceutical composition of claim ~~124~~ 122 in the manufacture of a medicament for treating a neurodegenerative disease in a subject.

~~134~~132. A method of preparing an antibody-drug conjugate comprising contacting a binding agent with a compound of claim ~~70~~68.

~~135~~133. The compound of claim ~~33~~32, having the following structure



or a pharmaceutically acceptable salt thereof.

~~136~~134. The compound of claim ~~33~~32, having the following structure



or a pharmaceutically acceptable salt thereof.

~~137~~135. The compound of claim ~~33~~32, having the following structure



or a pharmaceutically acceptable salt thereof.

~~138~~136. The compound of claim ~~33~~32, having the following structure



or a pharmaceutically acceptable salt thereof.

~~139~~137. The compound of claim ~~70~~68, having the following structure



or a pharmaceutically acceptable salt thereof.

~~140~~138. The compound of claim ~~70~~68, having the following structure



or a pharmaceutically acceptable salt thereof.

~~141~~139. The compound of claim ~~70~~68, having the following structure



or a pharmaceutically acceptable salt thereof.

~~142~~140. The compound of claim ~~68~~70, having the following structure



or a pharmaceutically acceptable salt thereof.

~~143~~141. The compound of claim ~~10~~9, having the following structure



~~144~~142. The compound of claim ~~10~~9, having the following structure



~~145~~143. The compound of claim ~~10~~9, having the following structure



~~146~~144. The compound of claim ~~10~~9, having the following structure



~~147~~145. The compound of claim ~~32~~31, selected from the group consisting of



PI;



PII-1;



PII-2;



PII-3;



PII-4;



PII-5;



PII-6;



PII-7;



PII-8;



PII-9;



PII-10;



PIII-1;



PIII-4;



PII-11;



PII-12;



PII-13;



PIII-5; and



PIV.

~~148~~146. The compound of claim ~~66~~65, selected from the group consisting of



L1-PI;



L1-PII-1;



L1-PII-2;



L1-PII-3;



L1-PII-4;



L1-PII-5;



L1-PII-6;



L1-PII-7;



L1-PII-8;



L1-PII-9;



L1-PII-10;



L1-PIII-1;



L2-PIII-1;



L3-PIII-1;



L4-PIII-1;



L5-PIII-1;



L1-PIII-4;



L6-PII-9;



L7-PII-1;



L4-PI;



L1-PII-11;



L1-PII-12;



L8-PII-1;



L9-PII-1;



L10-PII-1;



L11-PII-2;



L12-PII-2;



L13-PII-1;



L14-PII-1;



L15-PII-1;



L16-PII-1;



L17-PII-1;



L6-PII-13;



L18-PII-1;



L19-PIII-1;



L9-PIII-1;



L12-PIII-5;



L13-PIII-1;



L1-PIV; and



L14-PIV.

~~149~~147. A compound selected from the group consisting of





Q1L1-PI;



Q2L1-PII-1;





Q1L1-PII-2;



Q1L1-PII-3;



Q1L1-PII-4;



Q1L1-PII-5;



Q1L1-PII-6;



Q1L1-PII-7;



Q1L1-PII-8;



Q1L1-PII-9;



Q2L3-PIII-1;



Q1L5-PIII-1;



Q1L1-PII-1;



Q1L1-PIII-4;





Q2L6-PII-9;



Q2L7-PII-1;



Q1L1-PII-11;



Q1L1-PII-12;



Q1L6-PII-9;



Q1L7-PII-1;



Q1L15-PII-1;





Q1L17-PII-1;



Q1L6-PII-13;





Q1L13-PIII-1; and





Q1L1-PIV.

~~150~~148. The compound of claim 1, selected from the group consisting of





BA-L1-PII-1;





BA-L1-PIII-1;



BA-L2-PIII-1;



BA-L3-PIII-1;



BA-L4-PIII-1;





BA-L5-PIII-1;





BA-L14-PII-1;





BA-L6-PII-9;



BA-L13-PII-1; and



BA-L8-PII-1

wherein **BA** is an antibody or an antigen binding fragment thereof; and

k is an integer from one to four.